newsfilter
← Latest News
Business Wire·

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Are Encouraged by the Positive Governance and Operational Measures Implemented Under New Board Chair Kevin Tang Believe Shareholders Would Be Better Served by the Removal of CEO Peter Greenleaf, Who Has a Track Record